Leronlimab

from Wikipedia, the free encyclopedia
Leronlimab
other names
  • PA-14
  • PRO-140
Mass / length primary structure 146.67 kg mol −1
Identifier
External IDs
Drug information
DrugBank DB05941
Drug class CCR5 competitor

Leronlimab ( INN ) is a humanized monoclonal antibody being developed to treat graft-versus-host disease (GvHR) from HIV , breast cancer and COVID-19 .

Mechanism of action

Leronlimab binds to the CC motif chemokine receptor 5 (CCR5), the cells of the immune system such as T cells and macrophages expressed is. In this way it competitively prevents the binding of HIV-1 to the CD4 receptor and thus acts as an entry inhibitor . Numerous other pathophysiological processes , such as tumor invasion and metastasis , the pathogenesis of non-alcoholic steatohepatitis and the development of graft-versus-host diseases, involve the CC motif chemokine receptor 5 and can be influenced by Leronlimab.

Other Information

In Leronlimab is a humanized form of a mouse - IgG4 κ antibody which biotechnologically with the help of CHO cells is produced.

Leronlimab has fast track status in the United States for combination therapy with HAART in HIV-infected patients and for the treatment of patients with CCR5- positive metastatic triple negative breast cancer (mTNBC) . For use in COVID-19 patients, the FDA has granted Emergency Investigational New Drug (EIND) status.

Individual evidence

  1. ^ A b International Nonproprietary Names for Pharmaceutical Substances (INN) . In: World Health Organization (Ed.): WHO Drug Information . tape 32 , no. 3 , 2018, p. 466 f . (English, who.int [PDF]).
  2. ↑ Leronlimab - CytoDyn. In: AdisInsight. Springer, May 20, 2020, accessed on May 23, 2020 .
  3. ↑ Antiviral Briefs . In: AIDS Patient Care and STDs . tape  22 , no. 2 , February 9, 2008, p. 159 , doi : 10.1089 / apc.2008.9960 , PMID 18273941 (English).
  4. ↑ Kush Dhody, Nader Pourhassan, Kazem Kazempour, Derry Green, Shide Badri, Hana Mekonnen, Denis Burger, Paul J. Maddon: PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV 1 infection . In: HIV Clinical Trials . tape 19 , no. 3 , April 17, 2018, p. 85 , doi : 10.1080 / 15284336.2018.1452842 (English).
  5. ^ PRO 140 in Treatment-Experienced HIV-1 Subjects. In: ClinicalTrials.gov. US National Library of Medicine, April 16, 2019, accessed May 23, 2020 .
  6. ↑ Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection. In: ClinicalTrials.gov. US National Library of Medicine, February 11, 2019, accessed May 23, 2020 .
  7. ↑ A Compassionate Use Study of Leronlimab in Breast Cancer. In: ClinicalTrials.gov. US National Library of Medicine, March 18, 2020, accessed May 23, 2020 .
  8. ↑ Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5 + mTNBC. In: ClinicalTrials.gov. US National Library of Medicine, February 28, 2020, accessed May 23, 2020 .
  9. ↑ Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19. In: ClinicalTrials.gov. US National Library of Medicine, May 12, 2020, accessed May 23, 2020 .
  10. ↑ Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19). In: ClinicalTrials.gov. US National Library of Medicine, May 12, 2020, accessed May 23, 2020 .
  11. ↑ Alexandra Trkola, Thomas J. Ketas, Kirsten A. Nagashima, L. u. Zhao, Tonie Cilliers, Lynn Morris, John P. Moore, Paul J. Maddon, William C. Olson: Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140 . In: Journal of Virology . tape 75 , no. 2 , January 15, 2001, p. 579 , doi : 10.1128 / JVI.75.2.579-588.2001 (English).
  12. ↑ CCR5 CC motif chemokine receptor 5 (Homo sapiens / human). In: National Center for Biotechnology Information. US National Library of Medicine, May 17, 2020, accessed May 23, 2020 .
  13. ↑ Jeffrey M. Jacobson, Jacob P. Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag, Barry S. Zingman, Paul D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults . In: Antimicrobial Agents and Chemotherapy . tape 54 , no. 10 , April 26, 2010, p. 4137 , doi : 10.1128 / AAC.00086-10 (English).
  14. ↑ Entry on Leronlimab. In: Römpp Online . Georg Thieme Verlag, accessed on May 23, 2020.
  15. ↑ Leronlimab on www.drugs.com, accessed May 26, 2020.